LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...

Dexcom has launched its ONE+ continuous glucose monitoring (CGM) device in the UK, alongside a report that details high rates of anxiety and depression amongst type 2 diabetes (T2D) patients. The ...

Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...

Time in range is a powerful metric for modern diabetes management - but a new survey finds less than half of people with insulin-treated diabetes are even using it.1 A recent UK survey found that ...

Wider use of the Dexcom G6 real-time continuous glucose monitoring (RT-CGM) system in the United Kingdom would be cost-effective in the long term, new research suggests. The analysis was published in ...

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on ...

Truist Securities initiated coverage on DexCom (NASDAQ:DXCM) with a Buy rating and a $102.00 price target Monday, citing the company’s position in the continuous glucose monitoring market. According ...

DexCom , Inc. (NASDAQ:DXCM), a leader in the continuous glucose monitoring (CGM) market, has been navigating a complex landscape of opportunities and challenges in recent months. The company’s strong ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an ...